Lung Cancer Patients with Anaplastic Lymphoma Kinase Rearrangement Lose Affiliation with Labor Market at Diagnosis

Overview

Journal Lung Cancer Manag

Date 2024 May 31

PMID 38818369

Authors

Jon Lykkegaard Andersen

Jakob Sidenius Johansen

Edyta Maria Urbanska

Peter Meldgaard

Peter Hjorth-Hansen

Charlotte Kristiansen

Miroslaw Stelmach

Eric Santoni-Rugiu

Maiken Parm Ulhoi

Betina Hojgaard

Morten Sall Jensen

Anders Bondo Dydensborg

Christina Dunweber

Karin Holmskov Hansen

Affiliations

Soon will be listed here.

Abstract

The main purpose of the present study was to investigate the labor market affiliation of NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Nationwide retrospective study of all patients with NSCLC in Denmark diagnosed between 2012 and 2018. During the study period NSCLC patients had a median overall survival of 44.0 months and a 7.8-fold increase in disease prevalence. Six months prior to diagnosis, 81% of NSCLC patients ≤60 years of age were employed. At the end of the 18-month follow-up period, 36% were employed. NSCLC patients have prolonged survival following diagnosis, but a large fraction of patients lose affiliation with the labor market.

References

Marinelli D, Siringo M, Metro G, Ricciuti B, Gelibter A . Non-small-cell lung cancer: how to manage - and -rearranged disease. Drugs Context. 2022; 11. PMC: 9576009. DOI: 10.7573/dic.2022-3-1. View

Pacheco J, Gao D, Smith D, Purcell T, Hancock M, Bunn P . Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2019; 14(4):691-700. PMC: 7310567. DOI: 10.1016/j.jtho.2018.12.014. View

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

Schmid S, Cheng S, Chotai S, Garcia M, Zhan L, Hueniken K . Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022; 24(1):40-50. DOI: 10.1016/j.cllc.2022.09.007. View

Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-Finn C . Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv192-iv237. DOI: 10.1093/annonc/mdy275. View

Ricciardi S, Tomao S, de Marinis F . Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009; 10(1):28-35. DOI: 10.3816/CLC.2009.n.004. View

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

Hansen K, Johansen J, Urbanska E, Meldgaard P, Hjorth-Hansen P, Kristiansen C . Clinical outcomes of + non-small cell lung cancer in Denmark. Acta Oncol. 2023; 62(12):1775-1783. DOI: 10.1080/0284186X.2023.2263153. View

Vayr F, Savall F, Bigay-Game L, Soulat J, Chouaid C, Herin F . Lung cancer survivors and employment: A systematic review. Lung Cancer. 2019; 131:31-39. DOI: 10.1016/j.lungcan.2019.03.010. View

10.

Rebuzzi S, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M . Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021; 22(5). PMC: 7961376. DOI: 10.3390/ijms22052625. View

11.

Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T . Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. JAMA Netw Open. 2023; 6(12):e2347700. PMC: 10724778. DOI: 10.1001/jamanetworkopen.2023.47700. View

12.

Lauppe R, Nilsson F, Fues Wahl H, Lilja M, Vikstrom A, Asanin S . Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study. Acta Oncol. 2022; 61(11):1354-1361. DOI: 10.1080/0284186X.2022.2133972. View

13.

Pacheco J, Camidge D . Is long-term survival possible for patients with stage IV ALK+ non-small cell lung cancer?. Expert Rev Respir Med. 2019; 13(5):399-401. DOI: 10.1080/17476348.2019.1596028. View

14.

Roelen C, Koopmans P, Groothoff J, van der Klink J, Bultmann U . Sickness absence and full return to work after cancer: 2-year follow-up of register data for different cancer sites. Psychooncology. 2010; 20(9):1001-6. DOI: 10.1002/pon.1820. View

15.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

16.

Erichsen R, Lash T, Hamilton-Dutoit S, Bjerregaard B, Vyberg M, Pedersen L . Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010; 2:51-6. PMC: 2943174. DOI: 10.2147/clep.s9908. View

17.

Paltrinieri S, Fugazzaro S, Bertozzi L, Bassi M, Pellegrini M, Vicentini M . Return to work in European Cancer survivors: a systematic review. Support Care Cancer. 2018; 26(9):2983-2994. DOI: 10.1007/s00520-018-4270-6. View

18.

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

19.

Hjollund N, Breinholt Larsen F, Andersen J . Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scand J Public Health. 2007; 35(5):497-502. DOI: 10.1080/14034940701271882. View

20.

Butow P, Laidsaar-Powell R, Konings S, Lim C, Koczwara B . Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies. J Cancer Surviv. 2019; 14(2):114-134. DOI: 10.1007/s11764-019-00828-z. View